AstraZeneca halts late-stage lung cancer trial of volrustomig after interim analysis shows unlikely success
AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.
3 sourcesClinical trials
00